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Background: The benefits of universal meticillin-resistant Staphylococcus aureus (MRSA)
admission screening, compared with screening targeted patient groups and the additional
impact of discharge screening, are uncertain.
Aims: To quantify the impact of MRSA screening plus decolonization treatment on MRSA
infection rates. To compare universal with targeted screening policies, and to evaluate the
additional impact of screening and decolonization on discharge.
Methods: A stochastic, individual-based model of MRSA transmission was developed that
included patient movements between general medical and intensive care unit (ICU) wards,
and between the hospital and community, informed by 18 months of individual patient
data from a 900-bed tertiary care hospital. We simulated the impact of universal and
targeted [for ICU, acute care of the elderly (ACE) or readmitted patients] MRSA screening
and decolonization policies, both on admission and discharge.
Findings: Universal admission screening plus decolonization resulted in 77% (95% confi-
dence interval: 76e78) reduction in MRSA infections over 10 years. Screening only ACE
specialty or ICU patients yielded 62% (61e63) and 66% (65e67) reductions, respectively.
Targeted policies reduced the number of screens by up to 95% and courses of decoloni-
zation by 96%. In addition to screening on admission, screening on discharge had little
impact, with a maximum 7% additional reduction in infection.
Conclusions: Compared with universal screening, targeted screening substantially
reduced the amount of screening and decolonization required to achieve only 12% lower
reduction in infection. Targeted screening and decolonization could lower the risk of
resistance emerging as well as offer a more efficient use of resources.
Crown Copyright ª 2013 Published by Elsevier Ltd on behalf of the Healthcare Infection
Society. Open access under CC BY-NC-ND license.Introductionlth England, 61 Colindale
8327 6377.
(S.R. Deeny).
y Elsevier Ltd on behalf of theHealthcare-associated meticillin-resistant Staphylococcus
aureus (HA-MRSA) infections remain a major cause of morbidity
and mortality in hospitalized patients despite recent declines
in several European countries.1,2 In a large number of hospitals,Healthcare Infection Society.Open access under CC BY-NC-ND license.
S.R. Deeny et al. / Journal of Hospital Infection 85 (2013) 33e4434including all 153 Veterans Affairs hospitals in the USA and all
hospitals in the England and Wales National Health Service, the
current practice is to screen all patients for MRSA carriage on
hospital admission (a policy sometimes referred to as ‘universal
screening’).1,3e5 Such screening is usually accompanied by
patient isolation or ‘decolonization’ which is the use of topical
antimicrobial agents (such as mupirocin or chlorhexidine) to
suppress MRSA levels and reduce the risk of progression from
carriage to infection, and possibly of transmission to other
patients. When used, these measures are usually applied in
addition to non-specific interventions, such as enhanced hand
hygiene and infection prevention and control.3 In response to
the documented long-term carriage of MRSA and its impact on
hospital transmission, patients who are thought to be at risk of
carrying MRSA in a number of European countries (Denmark,
Norway and The Netherlands) complete a course of decoloni-
zation treatment in the community.6e8
Universal screening, and subsequent isolation and/or decol-
onization of HA-MRSA-positive patients, has the potential to be
cost-effective within the intensive care unit (ICU) setting e
provided resistance to decolonization treatments remains rare
and interventions are effective. However, the relevance of
different screening policies to lower-risk settings outside of the
ICU, such as general medical wards, is less clear.9
HA-MRSA colonization has been shown to be associated with
particular risk factors, for example, certain patient groups and
medical histories; and with patient movement characteristics,
such as longer than average length of hospital stay, recent
hospitalization and readmission.10,11 We hypothesized that
targeting groups of inpatients with an increased length of stay
or previous history of hospital admission could provide a more
efficient method (in terms of screens per positive patient
identified) of preventing and controlling HA-MRSA trans-
mission, when compared with universal screening. While we
recognize that the transmission of MRSA can occur in the
community, we focus our research here on the transmission and
control of HA-MRSA, which we refer to as MRSA for brevity.
To test this hypothesis and evaluate the impact of different
screening policies on MRSA infection rates throughout the whole
hospital, we performed a model-based analysis. Previous model-
ling work in this area has either focused on specific hospital units
or used simplified representations of complex and heterogeneous
patient movement patterns.7,9,12,13 We aimed to evaluate the
long-term impact of interventions in both high- and lower-risk
hospital wards and to account for the impact of medical spe-
cialties and realistic patient movement patterns between
differentwardtypesandbetweenthehospitalandthecommunity.
To characterize the complexity of patient movements
within the hospital, and between the hospital and community,
we analysed individual patient data and constructed a sto-
chastic individual-based model accordingly. Using this model,
we simulated MRSA transmission at an individual patient level
and control in the hospital and community, and assessed the
impact of targeted and universal admission and discharge
screening and subsequent decolonization therapy.
Methods
Model description
We developed a dynamic, stochastic, individual-based
model which simulated MRSA transmission in a hospital.Extending a previous model of a single ICU, we added non-ICU
wards, populated with general medical and ACE patients, and
simulated patient movements between these wards as well as a
realistic patient readmission process (Figure 1A).9 The non-ICU
wards were parameterized to simulate a general medical ward.
However, to avoid confusion with the general medical specialty
they are referred to as non-ICU wards when discussed in the
text.
The MRSA transmission and recovery processes, modelled
using a previously described approach, are shown schemati-
cally in Figure 1B.9 Parameters, adjusted for ward size, are
presented in Table I. Further details of the model structure,
implementation and MRSA transmission parameters process are
in Appendix A.Dataset analysis and patient movement parameters
To parameterize and inform the model we analysed an
anonymized dataset of all medical patients admitted to non-
ICU wards and all patients admitted to ICU wards in the
Royal Free Hospital, London between 29 October 2009 and
18 May 2011. Patient movement characteristics: length of
stay, daily probability of discharge, probability of ward
transfer and probability of readmission, were calculated for
each ward type and for both ACE and general medical spe-
cialties. Mean values are presented in Table I. Daily proba-
bilities of discharge were adjusted to account for the
increased length of stay associated with MRSA infection using
previously described methods.14 Further details of the data
analysis are in Appendix B and model parameterization in
Appendix C.Identification of risk groups and formulation of
intervention policies
The groups of patients targeted for intervention were
identified in two stages. The first-stage analysis of the ano-
nymized dataset showed that ACE patients had a longer than
average length of stay and higher rate of readmission, and
that all patients on their second or further admission had a
higher risk of subsequent readmission. We therefore included
these patient characteristics (different movement patterns
for ACE patients, and admission history-based readmission
probabilities) explicitly in the model design. Further details on
the identification of high-risk patients through data analysis
are in Appendix B. The second stage of identification, a
baseline simulation of MRSA transmission and patient move-
ment using the individual-based model, showed that three
patient groups maintained a high prevalence of MRSA coloni-
zation and infection incidence simply due to their movement
patterns. These were identified as high-risk groups for tar-
geted screening and intervention: (i) readmitted patients
discharged from hospital within the previous 365 days; (ii)
patients in the ICU; and (iii) ACE specialty patients. In the
baseline simulations, MRSA decolonization was only applied to
clinical cases of MRSA infection. All screening policies are
detailed in Table II; we assume 100% compliance with the
policies. Patients who screened MRSA positive underwent
MRSA decolonization treatment either in hospital or, if
screened positive upon discharge, in the community. The
decolonization parameters were derived from a previous
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Figure 1. Schematic diagram of (A) patient movement dynamics and (B) meticillin-resistant Staphylococcus aureus (MRSA) transmission
dynamics within the hospital and community. (A) Admission from the community (new admission and readmission), discharge and transfer
from the intensive care unit (ICU) and from the rest of the hospital. Thickness of lines represents the relative frequency of the movement
process. On admission, patients fill a vacated space either in the ICU or in non-ICU ward and are assigned to the general medical or acute
care of the elderly (ACE) specialty (as described in Appendix A). (B) Transmission dynamics in the ICU and non-ICU wards. Transitions
between these infection states are shown by solid lines. In the community only recovery from MRSA colonization can occur.
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Table I
Model parameters
Parameter ICU Non-ICU wards All wards Source
All
specialties
ACE
specialty
General
medical
specialty
All
specialties
Ward and hospital discharge
Daily probability of ward
discharge for susceptible
and MRSA-colonized patients
0.13 0.13 0.15 Mean of a distribution used in model,
estimated from individual-level
hospital data. Full distribution
presented in Appendix C.
Daily probability of ward
discharge for MRSA-infected
patients
0.08 0.09 0.12 Mean of a distribution used in model,
estimated from individual-level hospital
data. Full distribution presented in
Appendix C.
Daily probability of hospital
discharge given a ward
discharge
0.18 0.58 0.51 Mean of a distribution used in model,
estimated from individual-level hospital
data. Full distribution presented in
Appendix C.
Daily probability of transfer
between ward types
0.56 0.0036 0.00053 Mean of a distribution used in model,
estimated from individual-level hospital
data. Full distribution presented in
Appendix C.
Daily probability of death for
susceptible and MRSA-colonized
patients
0.02 0.007 ICU ward: mean of a 21-day distribution
used in model; full distribution
and method of estimation presented by
Robotham et al.9; non-ICU ward: per-day
probability estimated as described in
Appendix A
Daily probability of death for
MRSA-infected patients
0.03 0.0085 ICU ward: mean of a 21-day distribution
used in model; full distribution
and method of estimation presented by
Robotham et al.9; non-ICU ward: per-day
probability estimated as described in
Appendix A.
Readmission
Probability of readmission
1st hospital stay 0.26 0.31 0.26 Estimated from individual-level hospital
data as described in Appendix B.
2nd hospital stay 0.50 0.67 0.50 Estimated from individual-level hospital
data as described in Appendix B.
Time (days) between discharge
and readmission (mean)
96.69 Mean of a distribution used in model,
estimated from individual-level hospital
data. Full distribution presented in
Appendix C.
Probability that a patient will
be readmitted to the same
specialty
1 0.18 1 Estimated from individual-level
hospital data.
Hospital population
Prevalence of MRSA on first
admission
0.03 Literature11
Proportion of patients assigned
to ACE specialty
0.30 Estimated from individual-level
hospital data
Hospital beds 20 880 Hospital data
Transmission
Daily probability of cross-
colonization per source
0.00185 0.000049 ICU9; non-ICU wards: estimated as
described in Appendix A.
Daily probability of cross-
infection per source
0.0003 0 ICU9; non-ICU wards: estimated as
described in Appendix A.
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Table I (continued )
Parameter ICU Non-ICU wards All wards Source
All
specialties
ACE
specialty
General
medical
specialty
All
specialties
Daily probability of progression
from colonization to infection
0.047 0.016 ICU9; non-ICU wards: estimated as
described in Appendix A.
Duration of colonization (mean) 365 days Exponentially distributed with a mean
of 365 days.6,17
Duration of infection Until
discharge
Assumption
Screening
Sensitivity
Baseline intervention (clinical
cultures)
0.68 Values assume the use of conventional
culture9
Policies 2e25 (screening) 0.83 Values assume the use of chromogenic
agar9
Specificity
Baseline intervention (clinical
cultures)
0.88 Values assume the use of conventional
culture9
Policies 2e25 (screening) 0.83 Values assume the use of chromogenic
agar9
Turnaround time (days)
Baseline intervention (clinical
cultures)
4 Values assume the use of conventional
culture9
Policies 2e25 (screening) 3 Values assume the use of chromogenic
agar9
Decolonization (mupirocin and
chlorhexidine treatment for 5 days)
Proportion of treated patients who
are MRSA negative at treatment end
0.69 Estimated as described in Appendix D.
Daily probability of reversion to
MRSA-positive status for
successfully treated patients
0.13 Estimated as described in Appendix D.
Proportional reduction in
susceptibility to colonization
given exposure to one colonized
or infected patient
0.65 9
Proportional reduction in
susceptibility to infection
given exposure to one colonized
or infected patient
0.66 9
Proportional reduction in daily
probability of progression or
self-infection
0.31 9
ICU, intensive care unit; MRSA, meticillin-susceptible Staphylococcus aureus; ACE, acute care of the elderly.
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the absence of resistance to these agents; further details are
provided in Appendix D.9 The probability of relapse to an
MRSA-colonized state for a patient decolonized at the end of
treatment was estimated using a simple deterministic model,
parameterized from a literature search; this is described in
Appendix D. Policy assessments were based on 500 simulation
runs, for 10 years, discarding the first year’s results to allow
MRSA and patient dynamics to reach equilibrium. The mean of
the remaining nine-year reporting period was taken for all
outcome statistics. The reported 95% coverage intervals (CIs)for outcome statistics represent the 2.5th and 97.5th per-
centiles from the resulting distributions.Results
Output from baseline simulation of individual-based
models
In baseline model simulations, the mean rate of MRSA
infection was 52.4 (95% CI: 51.5e53.2) per 10,000 bed-days in
Table II
Policy number and target groups
Policy no. Screening and decolonization of:
Single
1 Baseline: No screening: treatment of
clinical cases only
2 All patients on admission and weekly
until discharge
3 All patients on admission
4 Patients discharged from hospital 365 days
previously on admission and weekly until
discharge
5 Patients discharged from hospital 365 days
previously on admission
6 Patients in ACE specialty on admission and
weekly until discharge
7 Patients in ACE specialty on admission
8 ICU patients on admission and weekly until
discharge
9 ICU patients on admission
10 All patients on discharge
11 Patients discharged from hospital 365 days
previously on discharge
12 Patients in ACE specialty on discharge
13 ICU patients on discharge
Combined
14 Policies 4 and 10
15 Policies 4 and 11
16 Policies 4 and 12
17 Policies 4 and 13
18 Policies 6 and 10
19 Policies 6 and 11
20 Policies 6 and 12
21 Policies 6 and 13
22 Policies 8 and 10
23 Policies 8 and 11
24 Policies 8 and 12
25 Policies 8 and 13
ACE, acute care of the elderly; ICU, intensive care unit.
S.R. Deeny et al. / Journal of Hospital Infection 85 (2013) 33e4438the ICU and 1.6 (1.6e1.7) per 10,000 bed-days in the whole
hospital including ICU wards. On average 8.1% (8.1e8.1) of all
patients, 9.7% (9.7e9.7) of ACE specialty patients and 14.2%
(14.2e14.3) of readmitted patients discharged from hospital
within the previous 365 days were colonized on admission. Of
all patients, 14.8% (14.8e14.9) were discharged while MRSA-
colonized. Of these patients, ACE and those with a prior
admission within 365 days of the current one had respectiveTable III
Proportion of colonized patients from each risk group; results from ba
Risk group Colonized on admission
Readmittedb 0.67 (0.64e0.67)
ACE specialtyc 0.31 (0.30e0.31)
ICU wardd 0.02 (0.02e0.03)
ACE, acute care of the elderly; ICU, intensive care unit. Values are mea
a Proportion of patients discharged colonized who will be readmitted
b Readmitted patients discharged from hospital less than 365 days pre
c Patients assigned to the ACE specialty.
d Patients admitted to an ICU (colonized on admission) or discharged iprobabilities of 46.4% (46.3e46.4) and 48.7% (48.5e48.8) of
returning to the hospital while still colonized. Combined, these
patients constituted the majority (93%) of patients who
remained colonized on a subsequent hospital admission
(Table III).
Impact of targeting risk groups
Screening all patients on admission and weekly thereafter
until discharge (policy 2) resulted in the largest [77% (95% CI:
76e78)] net reduction in MRSA infection in the whole hospital
over a nine-year period and a 76% (75e77) reduction in the ICU
(Figure 2A). However, the policy required screening 207.6
(207.4e207.7) patients per day and prevented one MRSA
infection for every 9700 screens (Figure 2C). By contrast, policy
8 (screening patients admitted to the ICU and weekly there-
after until discharge) resulted in screening 8.6 (8.5e8.7) pa-
tients per day, for a 73% (72e74) reduction in MRSA infections
in the ICU and 66% (65e67) reduction in the whole hospital
(Figure 2A). This policy prevented one MRSA infection in the
ICU for every 89 screens, and one infection in the whole hos-
pital for every 103 screens. This resulted in a reduction in the
number of screens carried out by 95% and courses of decolo-
nization treatment by 96% when compared with policy 2.
However, policy 8 reduced the number of total colonized
bed-days over nine years by only 25.4% (95% CI: 25.0e25.8),
whereas policies targeting the other risk groups: readmitted
patients discharged from hospital 365 days previously, and ACE
specialty patients (policies 4 and 6, respectively); achieved 43%
(43e43) and 56% (55e56) reductions in colonized bed-days and
57% (55e59) and 62% (61e63) net reductions in MRSA infection,
respectively. Policies 4 and 6 screened 59 (59e59) and 79
(79e79) patients per day respectively, therefore reducing the
number of screens by 72% (policy 4) and 66% (policy 6), and
reducing the number of decolonization treatments by 55%
(policy 4) and 45% (policy 6) compared with policy 2.
Impact of community decolonization
Screening and decolonization of patients upon discharge
decreased the proportion of patients colonized on admission by
between 76% (policy 13) and 76% (policy 10). However, further
reductions in MRSA infection rates were <1% for policies
14e16, 18e20 and 22e25 (Figure 2B) when additional screening
on discharge was implemented compared with screening on
admission alone. An exception to this was policy 17, which
targeted readmitted patients who had been discharged from
hospital 365 days previously on admission and additionally
screened ICU patients on discharge, which achieved anseline simulation
Colonized on discharge Readmitted colonizeda
0.44 (0.43e0.44) 0.49 (0.49e0.49)
0.49 (0.49e0.49) 0.46 (0.46e0.46)
<0.01 <0.01
n (CI).
colonized from each risk group.
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Figure 2. (A, B) Percentage reduction in infection in the intensive care unit (ICU) and in the whole hospital for each policy compared with
the baseline. (C, D) Percentage reduction in infections per 1000 screens in the ICU ward and whole hospital compared with the baseline.
(A, C) Single Policies (2e13) in which targeted screening and decolonization occur only on admission (red points) or discharge (green
points). (B, D) Combined Policies (14e25) in which targeted screening and decolonization occur on admission and additionally on
discharge. Policy numbers correspond to the policy descriptions listed in Table II. Solid points plot the mean percentage reduction in
infections. Transparent ellipses plot the 95% coverage intervals from 100 model simulations. Colours represent populations targeted for
screening and decolonization.
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compared with screening patients on admission alone.
Discussion
Previousmodels of MRSA transmission have examined amulti-
ward setting within a hospital with limited patient movement
dynamics.13,15 The model presented here is, to our knowledge,
the first attempt to account for the effect of heterogeneous
patient movement patterns associated with different specialties
and ward types on MRSA transmission dynamics and the effect of
screening and decolonization. The detailed description of pa-
tient movements both within the hospital and between the
hospital and community should allow a more realistic repre-
sentation of the overall transmission dynamics. For example,
high-risk groups in the non-ICU wards maintained a high preva-
lence of MRSA colonization (ACE medical specialty 25% andreadmitted patients 21%) purely through their increased length
of stay and high probability of readmission. The inclusion of the
‘feedback loop’ between hospital and community populations,
created by readmitted patients, also allowed the evaluation of
the long-term effects of interventions, as well as the impact of
community control on the hospital dynamics. The results of the
baseline simulation were consistent with rates of MRSA infection
reported through mandatory surveillance before the decline in
MRSA infection rates from 2005 onwards, as was the relative
prevalence of MRSA colonization on admission in readmitted and
ACE specialty patients.16
We selected risk groups based on high rate of MRSA infection
(ICU wards) and the increased prevalence of MRSA colonization
(ACE specialty and readmitted patients). Due to their high
prevalence of colonization and higher probability of read-
mission, ACE medical specialty and readmitted patients made
up the majority of patients who returned to hospital while still
S.R. Deeny et al. / Journal of Hospital Infection 85 (2013) 33e4440colonized with MRSA. Targeting these patient groups reduces
hospital transmission which, in turn, results in fewer patients
with MRSA on admission.
Whereas universal screening and decolonization likely played
a role in the reduced hospital rates of MRSA infection, it resulted
in a substantial screening and treatment burden. In addition to
the allocation of financial and human resources that universal
screening requires, subsequent mass decolonizationmay place a
selection pressure for the development of resistance to
commonly used agents such as mupirocin or chlorhexidine. We
show that targeting specific hospital patients with a high risk of
infection (such as those in ICU) substantially reduces the
screeningburdenandnumberofdecolonizationtreatmentswhile
resulting in only a 12% smaller reduction in infection compared
withuniversal screening. In low-risk settings (i.e.non-ICUwards),
targeting ACE patients reduced the burden of screening and
treatment by half, yet resulted in only an 8% smaller reduction in
infection compared with universal screening. Therefore inap-
propriate use of decolonizationwill bedecreasedwith a targeted
screening system as fewer false positives will be treated with
mupirocin/chlorhexidine. Hence targeted screening could lower
the risk of resistance emerging aswell as offeringamoreefficient
use of resources. Given that MRSA carriage may persist for well
over a year in a single patient, screening and successful decolo-
nization on discharge may help to reduce the burden of MRSA
colonization in readmitted patients.6 We found, however, that
the additional benefit of decolonization on discharge on the rate
of MRSA infection in the hospital was limited compared with
intervention during the hospital stay.
One limitationof ourmodelwas thatwedid not considerMRSA
transmission and infection in surgicalwards.Although surgery is a
high-risk setting for infection, this exclusion is necessitated by
the lack of data to estimate parameters needed to simulate pa-
tient movement and MRSA transmission robustly within such
wards. Another limitation was that we did not account for vari-
ation in the persistence of MRSA carriage in different patient
groups or heterogeneity of infection sites. We have considered
MRSA infection as a single type of event, but MRSA infection can
occur in multiple sites and the impact of different policies may
depend of the distribution of infection types. The model did not
consider the risk of universal decolonization adding to the
development of resistance to decolonization agents. Although
the prevalence of resistance to mupirocin and chlorhexidine
remains low, some studies document treatment failure associ-
ated with resistance.18e20 However, restricting the use of
mupirocin and/or chlorhexidine to a smaller number of patients
through targeted screening and treatment, aswe suggest here, is
likely to reduce selection for resistance. Further, if the benefit of
screening and treatment of all patients declines over time (e.g.
due to reduced MRSA prevalence), our findings that support
targeted rather than universal screening are strengthened.
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Model structure and implementation
The model was stochastic, discrete time (with a time unit of
one day) and individual-based. It tracked the MRSA status and
hospital exposure of a group of 100,000 individuals, 920 of
whom were assumed to be hospitalized at any one time. Each
individual had a number of associated attributes which were
updated every day. These attributes were: current MRSA status
[colonized, infected or MRSA free (susceptible)]; date therapy
to suppress MRSA carriage started (if currently in use); current
hospitalization status; time since the most recent hospital
admission; time since most recent hospital discharge; ward
type (ICU or non-ICU if currently hospitalized); medical spe-
cialty and whether the patient had been discharged from
hospital less than 365 days previously. These characteristics
determined a patient’s hospital movement parameters, the
probability of discharge and readmission on each day of stay
and identified patients as targets for intervention strategies.
Medical specialty and a tag corresponding to whether a
patient had been discharged from hospital 365 days previously
(readmission status) were assigned on hospital admission, and
retained for the rest of the hospital stay. Seventy percent of
patients were assigned to the general medicine specialty on
their first admission. The remainder were assigned to the acute
care of the elderly (ACE) medical specialty. The specialty of
patients was retained on a subsequent hospital admission with
a specified probability (Table I). Patient movement parameters
were calculated directly from a de-identified dataset of all
patients admitted to the 900-bed Royal Free National Health
Service Trust Hospital, London, between 29 October 2009 and
18 May 2011. These parameters are presented in Table I.
Readmitted patients were assigned to one of two groups:
patients who had been discharged from the hospital within 365
days prior to the current hospital admission; and ‘new admis-
sions’ or those patients who had last been discharged from
hospital more than a year previously.
Once discharged to the community, patients could be
readmitted to hospital at some time in the future. The read-
mission process was parameterized to reflect the patient
movement patterns seen in real hospital data, where the
probability of readmission increased after a second hospital
visit. The probability that a patient was readmitted was
dependent on the hospital visit number and the medical spe-
cialty; these parameters are presented in Table I. If scheduled
for readmission, a patient’s MRSA status on discharge was
retained. Clearance could occur during the time between
hospital discharge and readmission (Table I).
The model was implemented in Cþþ. The model was run for
10 years in each simulation; the first year’s results were dis-
regarded to allow MRSA and patient dynamics to reach equi-
librium. Five hundred simulation runs were performed for each
policy. Ninety-five percent coverage intervals (CIs) were
calculated for outcome statistics and represent the 2.5th and
97.5th percentiles from the resulting distributions.MRSA transmission dynamics
The MRSA transmission and recovery processes were derived
from previously described single ward processes.1 Each day,
Table A-I
Daily transmission transition probabilities and mechanism of
decolonization
Transition Transition probability of
patient m on day t
Decolonization
impact
Si/ Ci 1 ð1 qiÞ
P
ðCiðtÞþIiðtÞÞ qi ¼ qi(1 e dc)
Si/ Ii 1 ð1 iiÞ
P
ðCiðtÞþIiðtÞÞ ii ¼ ii(1 e di)
Ci/ Ii ri ri ¼ ri(1 e dp)
Si, susceptible patient in ward i.
Ci, colonized patient in ward i.
Ii, infected patient in ward i.
qi, daily probability of cross-colonization per source in ward i.
ii, daily probability of cross-infection per source in ward i.
ri, daily probability patient will progress from colonization to
infection.
dc, reduction in susceptibility to colonization given exposure to one
colonized or infected patient.
di, reduction in susceptibility to infection given exposure to one
colonized or infected patient.
dp, reduction in probability of progression to infection given patient
is colonized.
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ceptible; MRSA-colonized; and MRSA-infected. It was assumed
that the probability of a susceptible patient becoming colonized
(in non-ICU and ICU wards) or infected directly from susceptible
status (in ICU wards only through cross-infection) increased
linearly with the number of MRSA-positive patients (both colo-
nized and infected) on their ward. As described in Table A-I,
each day the probability that patientm inward i transitions from
susceptible to MRSA-colonized/infected depends on the total
number of colonized or infected patients in that ward on that
day and the daily individual probability of cross-colonization (q)
or infection (i) per source in ward i, i.e. daily patient suscepti-
bility to colonization and infection. Each day a patientm in ward
i will transition from susceptible to colonized if
ran < 1 ð1 qiÞ
P
ðCiðtÞþIiðtÞÞ;
from susceptible to infected if
ran < 1 ð1 iiÞ
P
ðCiðtÞþIiðtÞÞ;
and from colonized to infected if ran < ri, where ran is a
number randomly and repeatedly drawn from a uniform dis-
tribution (see Table A-I for parameter definitions). We assumed
that all colonized and infected patients were equally infectious
and that transmission occurred via a mass action process.
MRSA-colonized patients could also progress to MRSA infection
through self-infection, i.e. progression from a colonized to an
infected state, at a daily probability ri. Although colonized and
infected patients could transfer between wards, the trans-
mission dynamics of each ward were otherwise independent.
Recovery from MRSA colonization and infection
At the time of colonization or infection, the recovery date
for the patient was selected from an exponential distribution
with a mean of 365 days. A patient could be discharged colo-
nized from the hospital but an infected patient was assumed to
revert to a colonized state on discharge. The use of decoloni-
zation overrode the natural recovery processes.
MRSA transmission parameters
Transmission parameters specific to the ICU wards used in
the simulations were taken from previously published
research.1 Transmission parameters specific to the non-ICU
wards were the same as those previously used to describe
general medical wards by Robotham et al., where estimates of
the daily probability of colonization and infection given expo-
sure to one MRSA-positive patient were derived from previous
work fitting a continuous time multistate Markov model to
MRSA surveillance and infection data.1,2
Estimation of daily probability of death
The daily probability of death for patients (with and without
MRSA infection) in ICU had been estimated in previous research
using a time-dependent model.3 Estimates for the non-ICU ward
were taken fromprevious research.2 Themethod of estimation is
described in brief here. Using Dr Foster data 2008/2009 (for East
of England trusts, from Eastern Region Public Health Observa-
tory), the standardized mortality rate per 1000 discharges in
general medicine was 44.7. Assuming a mean length of stay ingeneral medicine of 6.3 days (Hospital Episode Statistics 2008/
2009), this would give a daily death probability of 0.007. The
death rate was adjusted to account for MRSA infection using the
method described by Robotham et al.1
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2009;170:1186e1194.Appendix B. Data analysis results
The length of stay in a ward ranged from less than one day to
174 days, with the majority of patients discharged from a ward
by the end of day 2 (63%, 8319/13105). The median length of
ward stay was 1 day [interquartile range (IQR): 0e4] for patients
in non-ICU wards and 6 days (IQR: 2e13) for patients in ICU
wards. The median length of stay in the hospital as a whole was
5 days (IQR: 2e11). This increased to 12 days (IQR: 4e12) for
patients with at least one ICU episode during their hospital stay.
We explored the dataset to examine heterogeneity in length
of stay among the main specialties. Of the two most common
specialties in the dataset (general medicine and ACE), patients
admitted to the ACE specialty had a median length of ward stay
of 3 days (IQR: 1e7) and a hospital stay of 9 days (IQR: 4e17).
Patients admitted to the general medicine specialty had an
average length of ward stay of 1 day (IQR: 0e3) and hospital
stay of 3 days (IQR: 2e7).
Table C-II
Daily probability of transfer from or to an ICU ward, conditional on
discharge from a ward but not the hospital
Day Non-ICU ward to ICU ICU to non-ICU ward
1 0.004 0.625
2 0.002 0.818
3 0.001 0.778
4 0.001 0.750
5 0.002 0.643
6 0.001 0.625
7 0.002 0.625
8 0.002 0.625
9 0.002 0.625
10 0.001 0.625
Table C-III
Daily probability of hospital discharge when a patient is discharged
from a ward, conditional on discharge from the ward that day
Day ICU ward Non-ICU ward
General medicine
and ACE specialties
ACE
specialty
General medical
specialty
1 0.063 0.727 0.666
2 0.156 0.404 0.538
3 0.188 0.410 0.544
4 0.203 0.482 0.552
5 0.205 0.510 0.529
6 0.186 0.528 0.534
7 0.207 0.670 0.528
8 0.181 0.565 0.571
9 0.173 0.660 0.402
10 0.178 0.617 0.429
11 0.192 0.727 0.462
12 0.200 0.404 0.365
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within 365 days of discharge. We excluded all hospital admis-
sions on or after 20/05/2010, i.e. 365 days before the last
admission recorded in thedataset. This restricted the dataset to
975 hospital admissions. For this group, 31% of patients were
readmitted within 365 days of discharge. The probability of
readmission increasedwith each additional hospital stay; 22% of
patients newly admitted to hospital went on to be readmitted
within 365 days of discharge, whereas 58% of patients attending
for their second or subsequent hospital stay within a one-year
period were readmitted.
The distribution of time between hospital stays was right-
skewed. Of those patients who were readmitted within 365
days of discharge, the median length of time between
discharge and readmission was 58 days (IQR: 17e149).
We restricted analysis of heterogeneity in readmission rates
to the twomost common specialties: generalmedicine and ACE.
The probability of readmission within one year of discharge for
general medicine patients was 0.20 (95% CI: 0.18e0.21),
compared with 0.31 (95% CI: 0.26e0.35) for those assigned an
ACE specialty. The length of time between discharge and
readmission had a median of 27 days (IQR: 12e99) for the ACE
specialty and 17 days (IQR: 7e34) for the general medicine
specialty. Using the c2-test we found no significant difference
(P > 0.9) between these two specialties in the distribution of
time between discharge and the next hospital admission.
Basedon theaboveanalysis the followingpatient groupswere
identified as at risk of MRSA colonization/infection due to their
movement patterns: patients admitted to the ICU (due to
increased lengthofward andhospital stay); patients admitted to
the ACE specialty (due to increased length of ward and hospital
stay and increased probability of prompt readmission following
discharge); and patients with a previous hospital admission
within the previous 365 days (due to increased probability of
further readmissions).Appendix C. Discharge distributions
Table C-I
Daily probability of discharge from a ward by the end of each day for patients in ICU and an non-ICU ward
Day ICU ward: all specialties (general medicine and ACE) Non-ICU ward: ACE specialty Non-ICU ward: general
medicine specialty
Susceptible and
MRSA-colonized
patients
MRSA-infected
patients
Susceptible and
MRSA-colonized
patients
MRSA-infected
patients
Susceptible and
MRSA-colonized
patients
MRSA-infected
patients
1 0.085 0.052 0.242 0.146 0.583 0.352
2 0.168 0.092 0.169 0.093 0.323 0.177
3 0.236 0.126 0.201 0.107 0.289 0.154
4 0.176 0.099 0.192 0.107 0.258 0.144
5 0.161 0.093 0.171 0.099 0.243 0.141
6 0.128 0.079 0.150 0.092 0.202 0.124
7 0.073 0.048 0.115 0.076 0.225 0.149
8 0.079 0.055 0.130 0.090 0.18 0.125
9 0.143 0.099 0.134 0.093 0.175 0.121
10 0.200 0.137 0.122 0.083 0.179 0.122
11 0.042 0.030 0.103 0.073 0.211 0.15
12 0.043 0.030 0.130 0.067 0.144 0.101
13 0.182 0.124 0.242 0.069 0.158 0.108
14 0.056 0.038 0.169 0.063 0.118 0.079
13 0.185 0.410 0.265
14 0.171 0.482 0.313
Table C-IV
Distribution of times between discharge and readmission
Month since discharge Proportion of patients readmitted
1 0.26
2 0.19
3 0.16
4 0.14
5 0.10
6 0.04
7 0.06
8 <0.01
9 0.05
10 <0.01
11 0.01
12 <0.01
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(decolonization) process and parameters
Topical MRSA suppression chemotherapy (sometimes
referred to as ‘decolonization’, and often making use of agents
such as mupirocin and chlorhexidine) may (i) reduce the daily
probability of acquiring MRSA if a treated patient is susceptible
at the beginning of treatment; (ii) reduce the daily probability
of transmission of MRSA from a colonized/infected patient
undergoing treatment; and (iii) reduce a colonized patient’s
probability of progression to MRSA infection while undergoing
treatment (the computational process is shown in Table A-I).
Parameter estimates for all three effects were taken from a
previously described study assuming a five-day course of
chlorhexidine gluconate and mupirocin and full susceptibility
to these agents.1
The probability that MRSA suppression chemotherapy cleared
MRSA carriage (causing an MRSA-colonized or infected patient to
revert to susceptible status and the probability that apparently
successfully treated patients (who were not colonized with
MRSA at the end of treatment) became recolonized with MRSA
before they were readmitted to hospital were estimated from
aggregate data collected as part of a literature review (following
the search criteria and selection method outlined by Robotham
et al.1). We developed a simple model (Equations 1 and 2) in
which a group of patients undergoing treatment, recovered from
MRSA colonization due to successful treatment, and successfully
treated patients could become recolonized with MRSA.
Equation 1:
d
dt
ðCÞ ¼ dS ssC
Equation 2:
d
dt
ðSÞ ¼ ssC dS
where:
C, colonized patients;
S, susceptible patients;
N ¼ C þ S, population of treated patients;
d, probability of reversion to MRSA-positive status for suc-
cessfully treated patients within one year;s, rate of treatment completing (1/Duration of treatment)
where duration of treatment is five days;
s, proportion of treated patients who are MRSA negative at
treatment end.
The model was fitted applying a least-squares method to the
collated proportion of treated patients that were MRSA sus-
ceptible over time.2e5 The proportion of successfully treated
patients and the probability of reversion to an MRSA-positive
status for successfully treated patients are presented in
Table I (main paper). The decolonization effectiveness par-
ameters were assumed to be the same in the ICU and non-ICU
settings and in the community.
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